This High-Flying Stock Just Got Some Bad News: Should You Sell?

Biotech giant Vertex Pharmaceuticals (VRTX 0.99%) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod in several countries. This development capped off another excellent year for the drugmaker, one during which -- as usual -- it crushed the market.However, at least on the clinical front, Vertex isn't exactly starting 2024 with a bang. The company recently released positive but somewhat disappointing data from a ph ...